Khalid Atallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Khalid Atallah has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Gehad Ahmed Saleh
Radiology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3 shared publicationsOmar Hamdy
Surgical Oncology Department, Oncology Center, Mansoura University, Mansoura, Egypt
3 shared publications- Ahmed Abdallah
Department of Surgical Oncology, OCMU Oncology Center - Mansoura University Faculty of Medicine, Mansoura, Egypt
1 shared publication - Ahmed Hashim
King's College Hospital, London, UK
1 shared publication Ahmed Hassan
Surgical Oncology Unit, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura
1 shared publication- Ahmed M. Abdellatif
Department of Otorhinolyrngolgy and Head & Neck Surgery, October 6 Insurance Hospital, Giza, Egypt
1 shared publication
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 38 (1) , 57
Uterine transposition for fertility preservation prior to pelvic irradiation: an initial Egyptian case series
Background: Recently, uterine transposition has been proposed as a novel technique for fertility preservation in young females undergoing radiation therapy for pelvic malignancies. Patients and methods: This is an interventional pilot study including six female patients with pelvic malignancies planned to receive pelvic radiation aiming at preserving their fertility after a multidisciplinary team decision to have uterine transposition. Our study aims to assess the feasibility of this novel technique. Results: Six patients underwent uterine transposition. Three of them were done through open technique, with successful repositioning. The other three patients underwent laparoscopic uterine transposition, one of them underwent repositioning and still receiving chemotherapy for Ewing’s sarcoma, the other two patients are still receiving radiation therapy after transposition. Unfortunately, one of them died of disease and adjuvant therapy complications four months after laparoscopic uterine transposition. Conclusion: Uterine transposition is a feasible procedure with safe outcomes. The preliminary results carry a promising hope for better fertility preservation in young patients undergoing radiation for pelvic malignancies.
- 11 August 2026
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 38 (1) , 57
Open AccessUterine transposition for fertility preservation prior to pelvic irradiation: an initial Egyptian case series
Background: Recently, uterine transposition has been proposed as a novel technique for fertility preservation in young females undergoing radiation therapy for pelvic malignancies. Patients and methods: This is an interventional pilot study including six female patients with pelvic malignancies planned to receive pelvic radiation aiming at preserving their fertility after a multidisciplinary team decision to have uterine transposition. Our study aims to assess the feasibility of this novel technique. Results: Six patients underwent uterine transposition. Three of them were done through open technique, with successful repositioning. The other three patients underwent laparoscopic uterine transposition, one of them underwent repositioning and still receiving chemotherapy for Ewing’s sarcoma, the other two patients are still receiving radiation therapy after transposition. Unfortunately, one of them died of disease and adjuvant therapy complications four months after laparoscopic uterine transposition. Conclusion: Uterine transposition is a feasible procedure with safe outcomes. The preliminary results carry a promising hope for better fertility preservation in young patients undergoing radiation for pelvic malignancies.
- Open Access
- 1 September 2025
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 41 (4) , 418-427
One-stage tunneled de-epithelialized deltopectoral flap for huge head and neck cancer defects in the era of free flaps
One-stage tunneled de-epithelialized deltopectoral flap for huge head and neck cancer defects in the era of free flaps - Turkish Journal of Surgery
- 1 September 2025
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 41 (4) , 418-427
Open AccessOne-stage tunneled de-epithelialized deltopectoral flap for huge head and neck cancer defects in the era of free flaps
One-stage tunneled de-epithelialized deltopectoral flap for huge head and neck cancer defects in the era of free flaps - Turkish Journal of Surgery
- Open Access
Omission of Axillary Surgery After Neoadjuvant Therapy in Her2-Positive Breast Cancer: Who Are the Candidates?
Background: This study aimed to evaluate the lymph node (LN) response in Her2-positive breast cancer patients who received neoadjuvant therapy (NAT) and to discuss if axillary staging can be omitted in these patients. Methods: This is a retrospective cohort study including patients with Her2+ breast cancer at our center from March 2022 to September 2023. Results: The study included 139 patients in the final analysis; 69.1% of the patients had HR+/Her2+ disease while 30.9% had HR−/Her2+ disease. Most of the included patients (129 patients = 92.8%) had initially node-positive or suspicious disease. A total of 112 patients (80.6%) showed clinically negative axillary LNs (cN0) after NAT. All of them showed pathologically node-negative disease. When comparing the pathological node-positive vs. -negative groups, the following was found to be statistically significant: degree of Her2 positivity, number of anti-Her2 cycles, pre- and post-neoadjuvant LN status, and primary tumor radiological and pathological response. Also, all T1 tumors before NAT showed negative LNs after NAT, but it was statistically non-significant. Conclusions: Axillary staging may be omitted in Her2+ patients with cN0 after NAT, especially those with early tumors, strong Her2+ disease, cN0 before NAT, and those in whom the primary tumor achieved a complete clinical response.
Open AccessOmission of Axillary Surgery After Neoadjuvant Therapy in Her2-Positive Breast Cancer: Who Are the Candidates?
Background: This study aimed to evaluate the lymph node (LN) response in Her2-positive breast cancer patients who received neoadjuvant therapy (NAT) and to discuss if axillary staging can be omitted in these patients. Methods: This is a retrospective cohort study including patients with Her2+ breast cancer at our center from March 2022 to September 2023. Results: The study included 139 patients in the final analysis; 69.1% of the patients had HR+/Her2+ disease while 30.9% had HR−/Her2+ disease. Most of the included patients (129 patients = 92.8%) had initially node-positive or suspicious disease. A total of 112 patients (80.6%) showed clinically negative axillary LNs (cN0) after NAT. All of them showed pathologically node-negative disease. When comparing the pathological node-positive vs. -negative groups, the following was found to be statistically significant: degree of Her2 positivity, number of anti-Her2 cycles, pre- and post-neoadjuvant LN status, and primary tumor radiological and pathological response. Also, all T1 tumors before NAT showed negative LNs after NAT, but it was statistically non-significant. Conclusions: Axillary staging may be omitted in Her2+ patients with cN0 after NAT, especially those with early tumors, strong Her2+ disease, cN0 before NAT, and those in whom the primary tumor achieved a complete clinical response.
- 1 March 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 20 (1) , 1-6
Frozen Section as an Intraoperative Guide to Tailor Surgical Staging in Early-Stage Endometrial Cancer
- 1 March 2022
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 20 (1) , 1-6
Frozen Section as an Intraoperative Guide to Tailor Surgical Staging in Early-Stage Endometrial Cancer
- Open Access
- 22 March 2021
- Published by PAGEPress Publications in Urogynaecologia
- Vol. 33 (1)
Giant leiomyoma of the urinary bladder: A case report
Urinary bladder leiomyoma is a rare tumour accounting for less than 0.5% of all urinary bladder tumours. Till now, less than 250 cases were documented with variable sizes, most of them were less than 10 cm in maximum diameter. Here we present a 68- year-old female patient with urinary bladder giant leiomyoma measuring about 13 cm. She presented with right loin pain. Postcontrast computed tomography of the abdomen and pelvis revealed a large posterolateral right-sided urinary bladder mass with moderate right hydroureteronephrosis. It was managed by partial cystectomy. The patient had an uneventful postoperative course. Postoperative pathological examination of the specimen confirmed giant leiomyoma of the urinary bladder.
- 22 March 2021
- Published by PAGEPress Publications in Urogynaecologia
- Vol. 33 (1)
Open AccessGiant leiomyoma of the urinary bladder: A case report
Urinary bladder leiomyoma is a rare tumour accounting for less than 0.5% of all urinary bladder tumours. Till now, less than 250 cases were documented with variable sizes, most of them were less than 10 cm in maximum diameter. Here we present a 68- year-old female patient with urinary bladder giant leiomyoma measuring about 13 cm. She presented with right loin pain. Postcontrast computed tomography of the abdomen and pelvis revealed a large posterolateral right-sided urinary bladder mass with moderate right hydroureteronephrosis. It was managed by partial cystectomy. The patient had an uneventful postoperative course. Postoperative pathological examination of the specimen confirmed giant leiomyoma of the urinary bladder.
- Open Access
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58, S68
152 HEPATITIS B PROPHYLAXIS POST LIVER TRANSPLANTATION WITH TENOFOVIR OR ENTECAVIR
- 1 April 2013
- Published by Elsevier in Journal of Hepatology
- Vol. 58, S68
Open Access152 HEPATITIS B PROPHYLAXIS POST LIVER TRANSPLANTATION WITH TENOFOVIR OR ENTECAVIR